Bioactive Materials, Год журнала: 2024, Номер 45, С. 551 - 566
Опубликована: Дек. 11, 2024
Язык: Английский
Bioactive Materials, Год журнала: 2024, Номер 45, С. 551 - 566
Опубликована: Дек. 11, 2024
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3038 - 3038
Опубликована: Март 26, 2025
Cardiovascular diseases (CVD), the leading cause of death worldwide, and their strong association with fibrosis highlight pressing need for innovative antifibrotic therapies. In vitro models have emerged as valuable tools replicating cardiac 'in a dish', facilitating study disease mechanisms serving platforms drug testing development. These in systems encompass 2D 3D models, each its own limitations advantages. offer high reproducibility, cost-effectiveness, high-throughput capabilities, but they oversimplify complex fibrotic environment. On other hand, provide greater biological relevance are more complex, harder to reproduce, less suited screening. The choice model depends on specific research question stage Despite significant progress, challenges remain, including integration immune cells optimizing scalability throughput highly biomimetic systems. Herein, we review recent focus shared characteristics remaining challenges, explore how organs could inspire novel approaches research, showcasing potential strategies that be adapted refine myocardial models.
Язык: Английский
Процитировано
0Bioactive Materials, Год журнала: 2024, Номер 45, С. 551 - 566
Опубликована: Дек. 11, 2024
Язык: Английский
Процитировано
2